Nuclear Acetyl-CoA Gatekeeping: How NAD+ Decline Reprograms Histone Methylation to Lock Senescence

Hypothesis

NAD+ decline during aging does not merely reflect lost redox capacity; it actively reshapes nuclear acetyl‑CoA availability, biasing histone acetylation toward a state that permits DOT1L‑mediated H3K79 methylation at promoters of senescence‑associated secretory phenotype (SASP) genes. This epigenetic switch creates a self‑reinforcing loop that suppresses repair pathways and locks cells into a low‑ambition, pro‑inflammatory mode.

Mechanistic Model

1. NAD+ drop reduces SIRT1/6 deacetylase activity → increased acetylation of cytosolic ACLY (ATP‑citrate lyase) and ACSS2 (acetyl‑CoA synthetase short‑chain family member 2).
2. Hyper‑acetylated ACLY shows reduced catalytic efficiency (as reported in [2]), lowering conversion of citrate to cytosolic acetyl‑CoA.
3. Cytosolic acetyl‑CoA falls while nuclear acetyl‑CoA rises modestly because ACSS2, which uses acetate, becomes more active and preferentially supplies the nucleus (acetyl‑CoA pools are compartmentalized).
4. Elevated nuclear acetyl‑CoA boosts p300/CBP activity at specific lysine residues on histone H3 (e.g., H3K18ac) that create a permissive chromatin environment for DOT1L binding.
5. DOT1L then methylates H3K79 (H3K79me2/me3) at SASP gene promoters, a mark associated with transcriptional elongation and sustained inflammation ([1] shows acetate can reverse histone hypoacetylation, implying the reverse manipulation can drive the opposite state).
6. H3K79 methylation sustains SASP transcription, which secretes IL‑6, IL‑8, MCP‑1, further damaging mitochondria and lowering NAD+ via CD38 activation, completing the loop.

Thus, the system interprets NAD+ loss as a signal to shift acetyl‑CoA flux toward nuclear histone acetylation that favors a methylation‑driven senescence program rather than a generic energy deficit.

Predictions and Falsifiable Tests

• Prediction 1: In aged murine muscle stem cells, nuclear acetyl‑CoA levels will be higher relative to cytosolic acetyl‑CoA compared with young cells, despite total cellular acetyl‑CoA being unchanged or decreased.

  • Test: Subcellular fractionation followed by LC‑MS/MS quantification of acetyl‑CoA in young (3 mo) vs old (24 mo) MuSCs.

• Prediction 2: Inhibition of ACLY (e.g., with SB‑204990) will exacerbate the nuclear acetyl‑CoA increase and augment H3K79me2 at SASP promoters, while overexpression of a de‑acetylation‑mimic ACLY mutant will blunt this effect.

  • Test: Treat MuSCs with ACLY inhibitor or transfect ACLY‑K→R (acetyl‑null) and measure H3K79me2 by ChIP‑qPCR at Il6 and Cxcl1 promoters.

• Prediction 3: DOT1L knockdown or pharmacological inhibition (EPZ‑5676) will reduce SASP secretion even when NAD+ is low, and will improve mitochondrial respiration as measured by OCR.

  • Test: siRNA against Dot1l or EPZ‑5676 treatment in old MuSCs supplemented with NAD+ precursor (NR) and assay IL‑6 ELISA and Seahorse OCR.

• Prediction 4: Acetate supplementation will rescue cytosolic acetyl‑CoA and lower nuclear acetyl‑CoA flux, decreasing H3K79me2 and SASP, but only if ACLY activity is intact.

  • Test: Provide sodium acetate (10 mM) to old MuSCs with or without ACLY inhibitor and assess subcellular acetyl‑CoA and SASP.

Potential Outcomes

If the data confirm higher nuclear/cytosolic acetyl‑CoA ratio coupled with elevated H3K79me2 at SASP loci, and manipulation of ACLY or DOT1L shifts the phenotype as predicted, the hypothesis is supported. Conversely, if nuclear acetyl‑CoA does not rise, or DOT1L inhibition fails to affect SASP despite NAD+ depletion, the model would be falsified, suggesting NAD+ loss acts through alternative routes.

Broader Implication

This framework reframes NAD+ decline not as a passive biomarker but as an active regulator of acetyl‑CoA compartmentalization that redirects epigenetic enzyme activity toward a methylation‑driven senescence state. It links the "downgrading ambitions" metaphor to a concrete metabolic‑epigenetic checkpoint that could be targeted by compartment‑specific acetyl‑CoA modulators or DOT1L inhibitors to restore cellular ambition without globally raising NAD+ levels.